CNTB (Connect Biopharma Holdings) Days Payable: 0.00 (As of Mar. 2026)


CNTB Connect Biopharma Holdings Ltd CNTB
7 GF Score
Price $2.38
! 3 Warning Signs
View Full Analysis

What is Connect Biopharma Holdings Days Payable?

Connect Biopharma Holdings CNTB +0.42% 7 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates CNTB with a GF Score™ of 7/100. The stock has 3 warning signs investors should review. Among 705 Biotechnology companies, Connect Biopharma Holdings ranks worse than 141843.83% on this metric.

Connect Biopharma Holdings's average Accounts Payable for the three months ended in Mar. 2026 was $3.14 Mil. Connect Biopharma Holdings's Cost of Goods Sold for the three months ended in Mar. 2026 was $0.00 Mil.

The historical rank and industry rank for Connect Biopharma Holdings's Days Payable or its related term are showing as below:

CNTB's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.36
* Ranked among companies with meaningful Days Payable only.

Connect Biopharma Holdings's Days Payable stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00). stayed the same

Connect Biopharma Holdings Days Payable Historical Data

* Premium members only.

The historical data trend for Connect Biopharma Holdings's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Connect Biopharma Holdings Days Payable Chart

Connect Biopharma Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Days Payable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Connect Biopharma Holdings Quarterly Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CNTB vs ENLV, SMNR, MENS: Days Payable Comparison

For the Biotechnology subindustry, Connect Biopharma Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Connect Biopharma Holdings Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Connect Biopharma Holdings's Days Payable distribution charts can be found below:

* The bar in red indicates where Connect Biopharma Holdings's Days Payable falls into.


CNTB
7GF Score
Connect Biopharma Holdings Ltd CNTB
Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Connect Biopharma Holdings Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Connect Biopharma Holdings's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

Days Payable (A: Dec. 2025 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2024 ) + Accounts Payable (A: Dec. 2025 )) / count ) / Cost of Goods Sold (A: Dec. 2025 )*Days in Period
=( (0.342 + 1.964) / 2 ) / 0*365
=1.153 / 0*365
=N/A

Connect Biopharma Holdings's Days Payable for the quarter that ended in Mar. 2026 is calculated as:

Days Payable (Q: Mar. 2026 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Dec. 2025 ) + Accounts Payable (Q: Mar. 2026 )) / count ) / Cost of Goods Sold (Q: Mar. 2026 )*Days in Period
=( (1.964 + 4.306) / 2 ) / 0*365 / 4
=3.135 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 0.00 mean?
Connect Biopharma Holdings (CNTB) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Connect Biopharma Holdings and its competitors. According to the industry distribution chart, Connect Biopharma Holdings ranks #999999 out of 705 companies in the Biotechnology industry.
Is Connect Biopharma Holdings' Days Payable too high?
Connect Biopharma Holdings' current Days Payable is 0.00. Based on the distribution chart, Connect Biopharma Holdings ranks #999999 out of 705 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Connect Biopharma Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Connect Biopharma Holdings' Days Payable compare to ENLV and SMNR?
According to the Biotechnology industry distribution chart, Connect Biopharma Holdings ranks #999999 out of 705 companies for Days Payable. This places Connect Biopharma Holdings in the lower half of its industry. The industry median Days Payable is 113.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Connect Biopharma Holdings and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Connect Biopharma Holdings's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Connect Biopharma Holdings stock overvalued right now?
Connect Biopharma Holdings (CNTB) has a current Days Payable of 0.00. The current Days Payable is 0.00. Connect Biopharma Holdings' overall GF Score™ is 7/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Connect Biopharma Holdings (CNTB), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Connect Biopharma Holdings Business Description

Address 3580 Carmel Mountain Road, Suite 200, San Diego, CA, USA, 92130
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
7GF Score

Get the complete analysis for CNTB

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.38
Price